← All trials
NCT05093634
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 26, 2021
- Last posted
- Oct 26, 2021
- Enrollment
- 560
- Arms / groups
- 5 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rhythm Pharmaceuticals, Inc.Lead sponsor
- Rhythm Pharmaceuticals, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.